Texila International Journal of Public Health
Special Issue-2024
DOI: 10.21522/TIJPH.2013.SE.24.05.Art017

Exploring the Interplay Between Polyphenols, Gut Microbiota, and Polycystic Ovary Syndrome (PCOD): A Comprehensive Review

Monisha Prasad[1]* and Navaneetha Krishnan S[2]
[1]*Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai–602105, India*
[2]*Department of Orthopaedics, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai–602105, India*

Abstract

Polycystic Ovary Syndrome (PCOD) is a common endocrine disorder in women of reproductive age, marked by hyperandrogenism, insulin resistance, and chronic anovulation. Emerging research indicates that the gut microbiota significantly contributes to the pathophysiology of PCOD, affecting both metabolic and hormonal balance. Polyphenols, bioactive compounds found in various foods, have shown promise in modulating gut microbiota composition and function, offering potential therapeutic benefits for PCOD. This review examines the intricate interplay between polyphenols, gut microbiota, and PCOD, focusing on how polyphenols may influence PCOD pathogenesis through gut microbiota modulation. We explore the alterations in gut microbiota observed in PCOD patients and how polyphenols may help restore microbial balance, potentially improving metabolic and reproductive health. The review also discusses the underlying molecular mechanisms, such as the regulation of inflammatory pathways, oxidative stress, and insulin signaling, through which polyphenols may exert their effects. By synthesizing findings from preclinical and clinical studies, we highlight the potential of dietary polyphenols as a complementary strategy in PCOD management, while also underscoring the need for more research to determine the most effective dietary interventions and polyphenol formulations. Understanding the relationship between polyphenols and gut microbiota in the context of PCOD offers promising new avenues for developing microbiota-targeted therapies that leverage the beneficial effects of polyphenols to improve outcomes for women with this condition.

Keywords: *Gut Microbiota, Hyperandrogenism, Insulin Resistance, Microbiota Modulation, Polycystic Ovary Disease (PCOD, Polyphenols.*

Introduction

Polycystic Ovary Syndrome (PCOD) is a common endocrine disorder affecting a significant number of women of reproductive age. Characterized by a constellation of symptoms including irregular menstrual cycles, hyperandrogenism, and polycystic ovaries, PCOD is often associated with a range of metabolic disturbances such as insulin resistance, obesity, and dyslipidemia. This multifaceted condition not only impairs reproductive health but also increases the risk of developing metabolic diseases such as type 2 diabetes and cardiovascular disorders. The pathophysiology of PCOD is complex and influenced by both genetic and environmental factors. Recent research has increasingly focused on understanding how dietary components and gut microbiota interact with these factors to influence PCOD outcomes [1].

Among the various dietary components, polyphenols have garnered significant attention due to their potential health benefits. Polyphenols are a diverse group of

Received: 16.09.2024 ***Accepted: 09.10.2024*** ***Published on: 10.12.2024***
Corresponding Author: monishaprasad.smc@saveetha.com

phytochemicals found abundantly in fruits, vegetables, tea, coffee, and whole grains. They possess antioxidant, anti-inflammatory, and metabolic regulatory properties that could play a crucial role in managing PCOD. Polyphenols, such as resveratrol, quercetin, and curcumin, have been shown to improve insulin sensitivity, reduce inflammation, and modulate lipid metabolism, all of which are beneficial in the context of PCOD. By influencing these pathways, polyphenols may help mitigate some of the metabolic and reproductive symptoms associated with PCOD [2]. The gut microbiota, the community of microorganisms residing in the gastrointestinal tract, is another critical factor influencing metabolic health. Emerging evidence suggests that the gut microbiota plays a significant role in regulating systemic inflammation, metabolic processes, and hormone levels. Dysbiosis, or an imbalance in gut microbiota composition, has been implicated in the development and progression of metabolic disorders, including PCOD [3]. Gut microbiota can interact with dietary polyphenols, affecting their bioavailability and metabolism. Moreover, the metabolites produced by gut microbiota can influence systemic inflammation and insulin sensitivity, thus potentially impacting PCOD outcomes [4].

The interplay between polyphenols and gut microbiota is a burgeoning area of research. Polyphenols can act as prebiotics, selectively promoting the growth of beneficial gut bacteria, while the gut microbiota can influence the metabolism of polyphenols, affecting their efficacy. This bidirectional interaction underscores the importance of considering both dietary components and gut health when evaluating strategies for managing PCOD [5]. Research indicates that polyphenol-rich diets may alter the gut microbiota composition favorably, leading to improved metabolic profiles and reduced inflammation. For instance, certain polyphenols have been shown to enhance the abundance of beneficial gut bacteria, which in turn can improve insulin sensitivity and reduce oxidative stress. These effects are particularly relevant for individuals with PCOD, as managing insulin resistance and inflammation is crucial for alleviating symptoms and preventing long-term complications [6].

Given the complexity of PCOD and the multifaceted roles of polyphenols and gut microbiota in its management, it is imperative to synthesize current research findings to better understand their interactions. This review aims to explore the current evidence on how polyphenols and gut microbiota impact PCOD, focusing on their mechanisms of action, potential therapeutic benefits, and the underlying biological pathways involved. By examining the latest research and identifying knowledge gaps, this review seeks to provide a comprehensive overview of the role of polyphenols and gut microbiota in managing PCOD. We aim to provide a detailed analysis of the mechanisms by which polyphenols and gut microbiota interact, assess the impact of these interactions on PCOD symptoms and progression, and suggest future research directions to explore these relationships further.

Understanding Polyphenols

Polyphenols are a large group of naturally occurring compounds found in plants, recognized for their health-promoting properties. These compounds are abundant in a variety of foods, including fruits, vegetables, tea, coffee, wine, and whole grains (Table 1). Polyphenols are categorized into several classes based on their chemical structure, including flavonoids, phenolic acids, stilbenes, and lignans. Among these, flavonoids are the most studied due to their potent antioxidant and anti-inflammatory activities. Resveratrol, quercetin, and catechins are some well-known polyphenols that have been extensively researched for their beneficial effects on human health [7]. Polyphenols exert their health benefits through multiple mechanisms. One of their primary roles is as antioxidants, where they scavenge free radicals and reduce oxidative stress, a key factor in the pathogenesis of various chronic diseases. They also exhibit anti-inflammatory properties by modulating signaling pathways involved in the inflammatory response, such as the NF-κB pathway. Additionally, polyphenols influence lipid metabolism, improving lipid profiles by reducing LDL cholesterol levels and increasing HDL cholesterol [8].

Table 1. Polyphenols, their Natural Sources, and Potential Activities

S. No.	Polyphenol	Sources	Potential Activity
1	**Epigallocatechin gallate (EGCG)**	Green tea, White tea	Antioxidant, anti-inflammatory, improves insulin sensitivity
2	**Quercetin**	Onions, apples, berries, red wine	Anti-inflammatory, reduces oxidative stress, modulates insulin signaling
3	**Resveratrol**	Red grapes, berries, peanuts	Anti-inflammatory, improves insulin sensitivity, reduces androgen levels
4	**Curcumin**	Turmeric	Anti-inflammatory, antioxidant, modulates gut microbiota
5	**Anthocyanins**	Berries (blueberries, raspberries), red cabbage	Antioxidant, anti-inflammatory, supports metabolic health
6	**Catechins**	Green tea, cocoa, apples	Antioxidant, anti-inflammatory, improves metabolic parameters
7	**Flavonoids**	Citrus fruits, parsley, celery	Anti-inflammatory, modulates gut microbiota, improves insulin sensitivity
8	**Lignans**	Flaxseeds, sesame seeds, whole grains	Antioxidant, modulates estrogen metabolism, improves gut health
9	**Phenolic acids**	Coffee, whole grains, berries	Antioxidant, anti-inflammatory, modulates gut microbiota
10	**Proanthocyanidins**	Grapes, cranberries, chocolate	Antioxidant, reduces inflammation, modulates insulin signaling
11	**Isoflavones**	Soybeans, legumes	Modulates estrogen receptors, improves insulin sensitivity
12	**Ellagic acid**	Pomegranates, strawberries, raspberries	Antioxidant, anti-inflammatory, modulates gut microbiota
13	**Chlorogenic acid**	Coffee, apples, pears	Antioxidant, improves glucose metabolism, anti-inflammatory
14	**Tannins**	Tea, wine, nuts	Antioxidant, modulates gut microbiota, reduces inflammation
15	**Genistein**	Soy products	Modulates estrogen receptors, antioxidant, improves insulin sensitivity
16	**Apigenin**	Parsley, celery, chamomile tea	Anti-inflammatory, antioxidant, modulates estrogen and androgen pathways
17	**Kaempferol**	Kale, spinach, broccoli, tea	Antioxidant, anti-inflammatory, modulates estrogen and androgen pathways
18	**Naringenin**	Citrus fruits (grapefruit, oranges)	Anti-inflammatory, improves lipid metabolism, modulates gut microbiota

19	**Hesperidin**	Citrus fruits (oranges, lemons)	Antioxidant, anti-inflammatory, improves insulin sensitivity
20	**Rutin**	Buckwheat, apples, citrus fruits	Antioxidant, anti-inflammatory, supports vascular health
21	**Gallic acid**	Grapes, tea, berries, nuts	Antioxidant, anti-inflammatory, modulates gut microbiota
22	**Fisetin**	Strawberries, apples, persimmons	Antioxidant, anti-inflammatory, modulates insulin signaling
23	**Daidzein**	Soybeans, legumes	Phytoestrogenic effects, modulates insulin sensitivity, antioxidant
24	**Baicalin**	Scutellaria baicalensis (Chinese skullcap)	Anti-inflammatory, antioxidant, modulates gut microbiota
25	**Silymarin**	Milk thistle	Antioxidant, liver protective, modulates insulin sensitivity
26	**Myricetin**	Berries, nuts, tea	Antioxidant, anti-inflammatory, supports glucose metabolism
27	**Oleuropein**	Olive oil, olive leaves	Anti-inflammatory, antioxidant, improves insulin sensitivity
28	**Rosmarinic acid**	Rosemary, oregano, basil	Antioxidant, anti-inflammatory, modulates gut microbiota
29	**Pterostilbene**	Blueberries, grapes	Antioxidant, anti-inflammatory, improves insulin sensitivity
30	**Coumarin**	Cinnamon, tonka beans, chamomile	Anti-inflammatory, antioxidant, modulates gut microbiota

In the context of PCOD, polyphenols have shown promise in addressing some of the metabolic disturbances associated with the condition. For example, resveratrol has been found to improve insulin sensitivity, a common issue in PCOD patients. Quercetin, another polyphenol, has been shown to reduce androgen levels and improve menstrual regularity, addressing both metabolic and reproductive aspects of PCOD. These effects are partly due to the ability of polyphenols to modulate pathways involved in glucose and lipid metabolism, as well as their impact on inflammation and oxidative stress [9]. Recent studies also suggest that polyphenols may influence hormone regulation, which is particularly relevant for PCOD, a condition characterized by hormonal imbalances. By modulating insulin and androgen levels, polyphenols may help alleviate some of the symptoms of PCOD. The interaction of polyphenols with the gut microbiota further enhances their therapeutic potential, as it may improve the bioavailability and efficacy of these compounds. Thus, understanding the diverse mechanisms through which polyphenols exert their effects is crucial for leveraging their benefits in managing PCOD [10].

Gut Microbiota

The gut microbiota refers to the diverse community of microorganisms, including bacteria, archaea, viruses, and fungi, that reside in the human gastrointestinal tract. This microbial ecosystem plays a crucial role in maintaining overall health by influencing digestion, metabolism, immune function, and even mood. The gut microbiota is composed of trillions of microorganisms, with bacteria being the most studied due to their significant impact on human physiology. The composition of the gut microbiota is highly dynamic and can be influenced by various factors, including diet, genetics, age, and environmental factors [11]. The gut microbiota contributes to host health through several mechanisms. One of its primary functions is the fermentation of dietary fibers into short-chain fatty acids (SCFAs), such as butyrate, propionate, and acetate. These SCFAs serve as energy sources for colon cells, regulate inflammation, and influence gut barrier integrity. Additionally, the gut microbiota is involved in the metabolism of bile acids, amino acids, and vitamins, further impacting metabolic processes [12].

In the context of metabolic health, gut microbiota has been implicated in the regulation of body weight, insulin sensitivity, and lipid metabolism. Dysbiosis, or an imbalance in gut microbiota composition, has been linked to various metabolic disorders, including obesity, type 2 diabetes, and PCOD. Emerging evidence suggests that dysbiosis may contribute to the development of PCOD by promoting systemic inflammation, insulin resistance, and hormonal imbalances. For instance, an overgrowth of certain pathogenic bacteria can lead to increased production of lipopolysaccharides (LPS), triggering inflammation and exacerbating insulin resistance [13]. The gut microbiota also plays a role in modulating the immune system. Healthy microbiota promotes the development of a balanced immune response, while dysbiosis can lead to chronic low-grade inflammation, a hallmark of many metabolic disorders, including PCOD. Understanding the basic functions and interactions of the gut microbiota is essential for exploring how it may influence the pathogenesis and management of PCOD. Modulating the gut microbiota through diet, probiotics, or prebiotics offers a promising approach to improving metabolic and reproductive outcomes in women with PCOD [14].

Mechanism of Polyphenols Enhancing Gut Microbiota in PCOD

Polyphenols exert their beneficial effects in PCOD management through a variety of mechanisms, with one of the most significant being their interaction with the gut microbiota (Table 2). Acting as prebiotics, polyphenols selectively promote the growth of beneficial gut bacteria, such as Bifidobacteria and Lactobacilli, which play a crucial role in maintaining gut health [15]. These beneficial bacteria metabolize polyphenols into bioactive compounds, such as short-chain fatty acids (SCFAs), which have systemic effects on host metabolism and inflammation. SCFAs, particularly butyrate, enhance insulin sensitivity, reduce inflammation, and improve lipid metabolism—key factors in managing PCOD [16].

Furthermore, polyphenols help maintain microbial diversity in the gut, preventing dysbiosis—a common feature in women with PCOD. By suppressing the growth of pathogenic bacteria and reducing endotoxin production, polyphenols decrease the translocation of lipopolysaccharides (LPS) into the bloodstream, thereby mitigating systemic inflammation [17]. This interaction between polyphenols and gut microbiota not only enhances gut health but also contributes to the overall management of PCOD by improving metabolic and reproductive outcomes [18].

Table 2. Role of Polyphenol and Gut microbiota in PCOD

Polyphenols Involved	Polyphenol Sources	Effects of Polyphenols on the Gut Microbiota	Impact on PCOD	Ref.
Quercetin	Apples, Onions, Berries	Promotes growth of beneficial bacteria such as *Bifidobacteria* and *Lactobacilli*	Enhances insulin sensitivity, reduces oxidative stress and inflammation	18
Catechins (e.g., EGCG)	Green tea, Dark chocolate	Inhibits growth of harmful bacteria like *Clostridium* spp., promotes *Bacteroides*	Reduces LPS translocation, lowers systemic inflammation and insulin resistance	18
Curcumin	Turmeric	Modulates gut inflammation, reduces pathogenic bacteria	Lowers systemic inflammation, improves insulin sensitivity, reduces hyperandrogenism	18
Resveratrol	Grapes, Blueberries, Peanuts	Enhances gut barrier function, promotes beneficial bacterial growth	Prevents LPS-induced inflammation, improves insulin sensitivity, balances hormones	18
Anthocyanins	Blueberries, Blackberries	Enhances growth of beneficial gut bacteria, reduces gut dysbiosis	Improves insulin sensitivity, reduces oxidative stress and inflammation	19
Caffeic Acid	Coffee, Whole grains	Increases SCFA production, particularly butyrate	Improves insulin sensitivity, reduces inflammation, supports metabolic health	20
Ferulic Acid	Rice bran, Oats, Wheat	Promotes growth of beneficial bacteria, increases SCFA production	Enhances insulin sensitivity, reduces oxidative stress and inflammation	20
Epigallocatechin Gallate (EGCG)	Green tea, Grapes	Suppresses harmful bacteria (*E. coli*), enhances beneficial bacteria	Reduces endotoxin production, decreases LPS translocation, mitigates systemic inflammation	19
Genistein	Soybeans, Chickpeas, Lentils	Promotes beneficial bacteria, modulates gut hormone interactions	Balances hormonal levels, reduces insulin resistance and inflammation	18
Daidzein	Soybeans, Red clover	Enhances growth of beneficial gut bacteria, modulates estrogen metabolism	Improves insulin sensitivity, supports hormone balance, reduces inflammation	19

Gut Microbiota and PCOD

The gut microbiota, a complex ecosystem of trillions of microorganisms, plays a pivotal role in the pathophysiology of PCOD. Women with PCOD often exhibit gut dysbiosis, characterized by a reduction in beneficial bacteria and an increase in pathogenic species. This imbalance is linked to metabolic disturbances, such as insulin resistance and chronic low-grade inflammation, which are central to PCOD. Gut bacteria produce SCFAs, which are crucial for maintaining metabolic health. In PCOD, the altered gut microbiota profile can lead to a reduction in SCFA production, exacerbating insulin resistance and systemic inflammation. Additionally, dysbiosis can influence the hypothalamic-pituitary-ovarian (HPO) axis, disrupting hormonal regulation and contributing to ovarian dysfunction [21]. The translocation of endotoxins like LPS into the bloodstream further amplifies inflammation and insulin resistance, worsening PCOD symptoms. Given the significant role of gut microbiota in PCOD, interventions aimed at restoring microbial balance, such as probiotics, prebiotics, and dietary modifications, hold promise as therapeutic strategies. These interventions can enhance the growth of beneficial bacteria, increase SCFA production, and reduce inflammation, thereby improving both metabolic and reproductive outcomes in PCOD [22].

Gut Microbiota-Derived Metabolites from Polyphenol Consumption

Polyphenol consumption leads to the production of various metabolites through complex interactions with gut microbiota, which significantly impacts host health. One of the primary outcomes of polyphenol metabolism in the gut is the generation of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. These SCFAs are produced when polyphenols are metabolized by gut bacteria, particularly those in the Firmicutes and Bacteroidetes phyla. SCFAs play crucial roles in maintaining gut homeostasis, modulating inflammation, and influencing systemic metabolism. For example, butyrate serves as a primary energy source for colonocytes, supports gut barrier integrity, and exerts anti-inflammatory effects by inhibiting nuclear factor-kappa B (NF-κB) signaling pathways [23].

In addition to SCFAs, polyphenol metabolism produces various phenolic acids, such as ferulic acid, caffeic acid, and hydroxybenzoic acids. These metabolites can be absorbed into the bloodstream and exert systemic effects. Phenolic acids have been shown to possess antioxidant and anti-inflammatory properties, contributing to reduced oxidative stress and inflammation in peripheral tissues [24]. They can modulate key signaling pathways, such as those involving nuclear receptors (e.g., PPARs) and transcription factors (e.g., NF-κB), thereby influencing systemic inflammation and metabolic processes [25].

Another critical aspect of polyphenol metabolism is the formation of urolithins, which are derived from ellagitannins and ellagic acid through microbial fermentation.

Urolithins have been demonstrated to exhibit significant health benefits, including antioxidant and anti-inflammatory effects. They also influence cellular processes such as autophagy and apoptosis, contributing to their potential role in preventing chronic diseases. Furthermore, polyphenol metabolism can affect the gut microbiota composition itself. For instance, the production of metabolites like SCFAs can create an environment that promotes the growth of beneficial bacteria, such as Lactobacillus and Bifidobacterium, while inhibiting the proliferation of pathogenic microorganisms. This modulation of gut microbiota composition can, in turn, impact overall metabolic health and disease states, including polycystic ovary syndrome (PCOD). Overall, the metabolites derived from polyphenol consumption through gut microbiota interactions play multifaceted roles in health [26]. By influencing gut microbiota composition, enhancing the production of beneficial metabolites, and modulating systemic inflammation and oxidative stress, these metabolites contribute to the therapeutic effects of polyphenols in various health conditions, including metabolic disorders and PCOD.

Health Implications of Gut-Derived Polyphenol Metabolites in PCOD

Gut-derived metabolites of polyphenols, such as short-chain fatty acids (SCFAs) and other bioactive compounds, have significant implications for managing Polycystic Ovary Syndrome (PCOD). These metabolites exert their effects through several mechanisms. Firstly, SCFAs like butyrate have potent anti-inflammatory properties, which are crucial in PCOD, where chronic low-grade inflammation often contributes to disease progression. By inhibiting nuclear factor kappa B (NF-κB) and promoting regulatory T cells, butyrate can reduce systemic inflammation, potentially improving ovarian function and metabolic outcomes [27].

Secondly, polyphenol-derived metabolites enhance insulin sensitivity, a key issue in PCOD due to its association with insulin resistance. SCFAs improve insulin sensitivity by enhancing glucose uptake in muscle cells and reducing hepatic glucose production, which helps in managing hyperglycemia and hyperinsulinemia. This improved insulin sensitivity can mitigate the risk of developing type 2 diabetes, a common concern in PCOD [28]. Moreover, polyphenol metabolites influence hormonal balance by affecting the gut microbiota. They can modulate the production and metabolism of sex hormones, such as estrogen and testosterone, which are often imbalanced in PCOD. For example, SCFAs can impact estrogen levels by altering estrogen-metabolizing enzyme expression, thereby addressing symptoms like menstrual irregularities and hirsutism.

Finally, polyphenols positively affect gut microbiota composition, shifting it towards a healthier balance. This shift supports the growth of beneficial bacteria, such as Bifidobacteria and Lactobacilli, while suppressing harmful bacteria. The resulting improvement in gut microbiota enhances metabolic health and reduces PCOD symptoms. Overall, gut-derived polyphenol metabolites play a crucial role in managing PCOD through their anti-inflammatory effects, enhancement of insulin sensitivity, regulation of hormonal balance, and modulation of gut microbiota, highlighting the potential benefits of incorporating polyphenol-rich foods into the diet [29].

Future Prospective

The intricate relationship between polyphenols, gut microbiota, and PCOD presents numerous opportunities for future research. One key area is the need for more clinical studies to confirm the efficacy of polyphenols in PCOD management [30, 31]. While preclinical studies have highlighted the potential benefits, well-designed human trials are essential to determine optimal dosing, safety, and long-term outcomes. Research should also explore which specific polyphenols or combinations are most effective in addressing the various aspects of PCOD, including insulin resistance, hormonal imbalance, and inflammation [32, 33]. Another promising avenue is the investigation of gut microbiota's role in PCOD. Longitudinal studies that track changes in gut microbiota composition over time about PCOD symptom development could provide valuable insights into causality and inform targeted therapies. Personalized medicine approaches, such as tailoring probiotic and dietary interventions based on individual gut microbiota profiles, offer the potential for more effective treatments [34].

Additionally, exploring the synergistic effects of polyphenols and gut microbiota modulation in PCOD could lead to the development of novel therapeutic strategies. Understanding how polyphenols influence gut microbiota composition and how these changes impact PCOD symptoms could pave the way for innovative approaches that combine diet and microbiota-targeted therapies. In conclusion, advancing research in these areas holds great promise for improving PCOD management, potentially leading to more effective, targeted, and personalized therapeutic strategies.

Conclusion

The intricate relationship between gut-derived polyphenol metabolites and Polycystic Ovary Syndrome (PCOD) underscores the potential of dietary interventions in managing this complex condition. These metabolites, particularly short-chain fatty acids (SCFAs), offer a multifaceted approach to addressing PCOD's underlying mechanisms, including chronic inflammation, insulin resistance, hormonal imbalances, and dysbiosis of the gut microbiota. By harnessing the anti-inflammatory, insulin-sensitizing, and hormone-modulating properties of polyphenols, and their ability to foster a healthier gut microbiome, there is a promising avenue for improving PCOD symptoms and overall metabolic health. Thus, integrating polyphenol-rich foods into the diet could serve as an effective, complementary strategy for managing PCOD, paving the way for future research and clinical applications in this field.

Conflict of Interest

The authors hereby declare that there is no conflict of interest.

Acknowledgement

The authors would like to thank Saveetha Medical College and Hospital for providing facilities to carry out this work.

Reference

[1]. Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., Kumar, M., 2023, Polycystic ovary syndrome: Etiology, current management, and future therapeutics. *Journal of Clinical Medicine*, 12(4), 1454, https://doi.org/10.3390/jcm12041454

[2]. Tsao, R., 2010, Chemistry and biochemistry of dietary polyphenols. *Nutrients,* 2(12), 1231–1246, https://doi.org/10.3390/nu2121231

[3]. Shanmugam, G., 2024, Polyphenols: Potent protectors against chronic diseases. *Natural Product Research*, 1–3, https://doi.org/10.1080/14786419.2024.2386402

[4]. Wu, H. J., & Wu, E., 2012, The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes,* 3(1), 4–14, https://doi.org/10.4161/gmic.19320

[5]. Ray, S. K., & Mukherjee, S., 2021, Evolving interplay between dietary polyphenols and gut microbiota—An emerging importance in healthcare. *Frontiers in Nutrition*, 8, 634944, https://doi.org/10.3389/fnut.2021.634944

[6]. Kasprzak-Drozd, K., Oniszczuk, T., Stasiak, M., & Oniszczuk, A., 2021, Beneficial effects of phenolic compounds on gut microbiota and metabolic syndrome. *International Journal of Molecular Sciences*, 22(7), 3715, https://doi.org/10.3390/ijms22073715

[7]. Rudrapal, M., Khairnar, S. J., Khan, J., Dukhyil, A. B., Ansari, M. A., Alomary, M. N., Alshabrmi, F. M., Palai, S., Deb, P. K., & Devi, R., 2022, Dietary polyphenols and their role in oxidative stress-induced human diseases: Insights into protective effects, antioxidant potentials, and mechanism(s) of action. *Frontiers in Pharmacology*, 13, 806470, https://doi.org/10.3389/fphar.2022.806470

[8]. Yan, Z., Zhong, Y., Duan, Y., Chen, Q., & Li, F., 2020, Antioxidant mechanism of tea polyphenols and its impact on health benefits. *Animal Nutrition*, 6(2), 115–123, https://doi.org/10.1016/j.aninu.2020.01.001

[9]. Chavez, G. N., Jaworsky, K., & Basu, A., 2023, The effects of plant-derived phytochemical compounds and phytochemical-rich diets on females with polycystic ovarian syndrome: A scoping review of clinical trials. *International Journal of Environmental Research and Public Health*, 20(15), 6534, https://doi.org/10.3390/ijerph20156534

[10]. Zhou, P., Feng, P., Liao, B., Fu, L., Shan, H., Cao, C., Luo, R., Peng, T., Liu, F., & Li, R., 2024, Role of polyphenols in remodeling the

host gut microbiota in polycystic ovary syndrome. *Journal of Ovarian Research*, 17(1), 69, https://doi.org/10.1186/s13048-024-01354-y

[11]. Shreiner, A. B., Kao, J. Y., & Young, V. B., 2015, The gut microbiome in health and in disease. *Current Opinion in Gastroenterology*, 31(1), 69–75, https://doi.org/10.1097/MOG.0000000000000139

[12]. Thursby, E., & Juge, N., 2017, Introduction to the human gut microbiota. *The Biochemical Journal,* 474(11), 1823–1836, https://doi.org/10.1042/BCJ20160510

[13]. Guo, H., Luo, J., & Lin, H., 2023, Exploration of the pathogenesis of polycystic ovary syndrome based on gut microbiota: A review. *Medicine,* 102(50), e36075, https://doi.org/10.1097/MD.0000000000036075

[14]. Li, Y., Zhu, Y., Li, D., Liu, W., Zhang, Y., Liu, W., Zhang, C., & Tao, T., 2023, Depletion of gut microbiota influents glucose metabolism and hyperandrogenism traits of mice with PCOS induced by letrozole. *Frontiers in Endocrinology*, 14, 1265152, https://doi.org/10.3389/fendo.2023.1265152

[15]. Wang, X., Qi, Y., & Zheng, H., 2022, Dietary polyphenol, gut microbiota, and health benefits. *Antioxidants*, 11(6), 1212, https://doi.org/10.3390/antiox11061212

[16]. Cuciniello, R., Di Meo, F., Filosa, S., Crispi, S., & Bergamo, P., 2023, The antioxidant effect of dietary bioactives arises from the interplay between the physiology of the host and the gut microbiota: Involvement of short-chain fatty acids. *Antioxidants,* 12(5), 1073, https://doi.org/10.3390/antiox12051073

[17]. Ramamurthy, J., 2024, Evaluation of antimicrobial activity of nanoformulated grape seed oil against oral microbes: An in vitro study. *World Journal of Dentistry*, 15(1), 43–49, https://doi.org/10.5005/jp-journals-10015-2360

[18]. Shabbir, U., Rubab, M., Daliri, E. B., Chelliah, R., Javed, A., & Oh, D. H., 2021, Curcumin, quercetin, catechins and metabolic diseases: The role of gut microbiota. *Nutrients,* 13(1), 206, https://doi.org/10.3390/nu13010206

[19]. Reygaert, W. C., 2018, Green tea catechins: Their use in treating and preventing infectious diseases. *BioMed Research International*, 2018, 9105261, https://doi.org/10.1155/2018/9105261

[20]. Fan, F. Y., Sang, L. X., & Jiang, M., 2017, Catechins and their therapeutic benefits to inflammatory bowel disease. *Molecules,* 22(3), 484, https://doi.org/10.3390/molecules22030484

[21]. Sun, Y., Gao, S., Ye, C., & Zhao, W., 2023, Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications. *Frontiers in Cellular and Infection Microbiology,* 13, 1142041, https://doi.org/10.3389/fcimb.2023.1142041

[22]. Hamamah, S., Iatcu, O. C., & Covasa, M., 2024, Nutrition at the intersection between gut microbiota eubiosis and effective management of type 2 diabetes. *Nutrients,* 16(2), 269, https://doi.org/10.3390/nu16020269

[23]. Zhang, Y., Yu, W., Zhang, L., Wang, M., & Chang, W., 2022, The interaction of polyphenols and the gut microbiota in neurodegenerative diseases. *Nutrients,* 14(24), 5373, https://doi.org/10.3390/nu14245373

[24]. Abdelsalam, S. A., Renu, K., Zahra, H. A., Abdallah, B. M., Ali, E. M., Veeraraghavan, V. P., Sivalingam, K., Ronsard, L., Ammar, R. B., Vidya, D. S., Karuppaiya, P., Al-Ramadan, S. Y., & Rajendran, P., 2023, Polyphenols mediate neuroprotection in cerebral ischemic stroke—An update. *Nutrients,* 15(5), 1107, https://doi.org/10.3390/nu15051107

[25]. Kumar, N., & Goel, N., 2019, Phenolic acids: Natural versatile molecules with promising therapeutic applications. *Biotechnology Reports,* 24, e00370, https://doi.org/10.1016/j.btre.2019.e00370

[26]. Anantharaju, P. G., Gowda, P. C., Vimalambike, M. G., & Madhunapantula, S. V., 2016, An overview on the role of dietary

phenolics for the treatment of cancers. *Nutrition Journal,* 15(1), 99, https://doi.org/10.1186/s12937-016-0217-2
[27]. He, F. F., & Li, Y. M., 2020, Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: A review. *Journal of Ovarian Research,* 13(1), 73, https://doi.org/10.1186/s13048-020-00670-3
[28]. Williamson, G., & Sheedy, K., 2020, Effects of polyphenols on insulin resistance. *Nutrients,* 12(10), 3135, https://doi.org/10.3390/nu12103135
[29]. Zhou, M., Yu, J., Li, X., Ruan, Z., & Yu, S., 2024, Role of the gut microbiota and innate immunity in polycystic ovary syndrome: Current updates and future prospects. *Journal of Cellular and Molecular Medicine,* 28(8), e18258, https://doi.org/10.1111/jcmm.18258
[30]. Bharali, M. D., Rajendran, R., Goswami, J., Singal, K., & Rajendran, V., 2022, Prevalence of polycystic ovarian syndrome in India: A systematic review and meta-analysis. *Cureus,* 14(12), e32351, https://doi.org/10.7759/cureus.32351
[31]. Islam, M. T., Mazumder, S., Aniqa, F. T., Uddin, N., Rahman, M. A., Sarkar, C., Mondal, M., Mubarak, M. S., & Rengasamy, K. R. R., 2024, Investigating the hepatoprotective properties of thymol against paracetamol-induced hepatotoxicity. *Food Bioscience,* 60, 104498, https://doi.org/10.1016/j.fbio.2023.104498
[32]. Azizi, A., Mumin, N. H., & Shafqat, N., 2021, Phytochemicals with anti 5-alpha-reductase activity: A prospective for prostate cancer treatment. *F1000 Research*, 10, 221, https://doi.org/10.12688/f1000research.51066.3
[33]. Sinan, K. I., Sut, S., Zengin, G., Dall'Acqua, S., Bouyahya, A., Uba, A. I., Ponniya, S. K. M., & Rengasamy, K. R. R., 2024, Integration of chemical characterization, biological activities, and network pharmacology of different extracts from Syzygium rowlandii. *Journal of Molecular Structure,* 1299, 137117, https://doi.org/10.1016/j.molstruc.2023.137117
[34]. Liu, J., Liu, Y., & Li, X., 2023, Effects of intestinal flora on polycystic ovary syndrome. *Frontiers in Endocrinology,* 14, 1151723, https://doi.org/10.3389/fendo.2023.1151723